Peptide receptor expression in GEP-NET.

Peptide receptor expression in GEP-NET. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Peptide receptor expression in GEP-NET. Abstract Text:

Jean Claude Reubi,Jean Claude Reubi,

Numerous peptide receptors have recently been reported to be expressed or overexpressed in various human cancers. For instance, somatostatin receptors are particularly frequently expressed in gastroenteropancreatic neuroendocrine tumors (GEP-NET), including both primaries and metastases. The density is often high, and the distribution is usually homogenous. While various somatostatin receptor subtypes can be expressed in these tumors, the sst(2) is clearly predominant. These receptors represent the molecular basis for a number of clinical applications, including symptomatic therapy with octreotide in hormone-secreting GEP-NET, in vivo diagnostic with radiolabeled diethylene triamine pentaacetic acid octreotide (Octreoscan) to evaluate the extend of the disease, and (90)Y- or (177)Lu-[(90)Y-DOTA]-D: -Phe(1)-Tyr(3) octreotide radiotherapy. GEP-NET can, however, express peptide receptors other than somatostatin receptor: Insulinomas have more glucagon-like peptide 1 receptors than somatostatin receptors; gastrinomas express very high levels of secretin receptors. GEP-NET may also express cholecystokinin 2, bombesin, neuropeptide Y, or vasoactive intestinal peptide receptors. Often, several of these peptide receptors are expressed simultaneously in GEP-NET, providing a molecular basis for in vivo multireceptor targeting of those tumors.

Peptide receptor expression in GEP-NET. Publishing Authors By Initials

JC Reubi,JC Reubi,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Peptide receptor expression in GEP-NET. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Virchows Archiv : an international journal of path

VOLUME: 451 Suppl 1

Page Numbers: S47-50

Journal Abbreviation: Virchows Arch.

ISSN: 0945-6317

DAY: 8

MONTH: 08

YEAR: 2007

Peptide receptor expression in GEP-NET. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9423843

Peptide receptor expression in GEP-NET. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Peptide receptor expression in GEP-NET. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Peptide receptor expression in GEP-NET.

AFFILIATION: Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, P.O. Box 62, Murtenstrasse 31, CH-3010, Berne, Switzerland. reubi@pathology.unibe.ch

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Virchows Arch

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Peptide receptor expression in GEP-NET Related Publications

• Blood pressure, circulating renin and the body sodium/volume state in patients with mild renal failure.
• CRF receptors in the rodent and human cardiovascular systems: species differences.
• GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung.
• Haemodynamic and blood volume studies in long-term haemodialysis patients, and in patients with successfully transplanted kidneys.
• Not Available
• Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms.
• Peptide receptor expression in GEP-NET.
• Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
• Secretin receptors in the human liver: expression in biliary tract and cholangiocarcinoma, but not in hepatocytes or hepatocellular carcinoma.
• The effect of cochlear nerve lesion on the release of glutamate, aspartate, and GABA from cat cochlear nucleus, in vitro.
• Wild-type and splice-variant secretin receptors in lung cancer: overexpression in carcinoid tumors and peritumoral lung tissue.
• [ALDOMET IN THE AMBULATORY TREATMENT OF HYPERTENSION. PERSONAL EXPERIENCES AND STUDIES ON RENAL HEMODYNAMICS.]
• [Are the so-called cerebroactive drugs really useful?]
• [Conservative therapy of chronic renal failure]
• [Exchangeable sodium, fluid space and hypertonia in chronic uremia]
• [Hemodynamic properties of two new phthalazine derivatives.]
• [Immunosuppression]
• [Importance of Kaplan's hypertension testing the etiologic diagnosis of hypertension]
• [Kidney function and antibiotic dosage]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Practical recommendations for antihypertensive therapy (author's transl)]
• [The behavior of renal hemodynamics in hydroxydione anesthesia.]
• [The classification of glomerulonephritis (author's transl)]
• [The present status of treatment of chronic renal insufficiency.]
• [Therapeutic tests and "ex juvantibus" diagnosis (author's transl)]
• [Treatment of circulatory collapse and shock.]
• [What the general practitioner should know about electrolytes.]